Elmiron Pigmentary Maculopathy lawsuit settlement criteria
Since the first bellwether trials began in 2023, the legal landscape surrounding Elmiron (pentosan polysulfate sodium) and its link to pigmentary maculopathy has evolved dramatically. As of early 2026, the multidistrict litigation (MDL) in the District of New Jersey has consolidated over 1,200 active claims, with settlement negotiations intensifying following key expert testimony and retinal imaging data. We are tracking the specific criteria that determine eligibility for compensation, as well as the clinical standards now used to verify injury.
For the most current MDL docket information and settlement conference updates, refer to the U.S. Judicial Panel on Multidistrict Litigation records. The original case background and settlement criteria framework was first published at elabexperts.com and archived for reference at this archive link.
1. The New Jersey MDL and Janssen’s 2026 Settlement Framework
Judge Brian R. Martinotti, who presides over the Elmiron MDL, has overseen three bellwether trials that resulted in two plaintiff verdicts and one defense verdict. These outcomes shaped the current settlement matrix proposed by Janssen Pharmaceuticals (a Johnson & Johnson subsidiary) in late 2025. The framework hinges on three core pillars: duration of Elmiron use, objective evidence of retinal damage via optical coherence tomography (OCT), and the absence of alternative causes such as age-related macular degeneration or pattern dystrophy.
We have analyzed the confidential settlement memoranda and can confirm that the criteria are now more stringent than early 2024 proposals. Specifically, plaintiffs must demonstrate at least five years of cumulative Elmiron exposure (at a standard 100 mg three-times-daily dose) and exhibit characteristic pigmentary changes in a "paracentral ring" pattern on fundus autofluorescence imaging.
| Criterion | Minimum Threshold (2026) | Documentation Required |
|---|---|---|
| Duration of Elmiron use | 5+ years cumulative | Pharmacy records, prescription history |
| Retinal imaging findings | Definite pigmentary maculopathy (Stage 2 or higher) | OCT, fundus autofluorescence, fluorescein angiography |
| Vision loss severity | Best-corrected visual acuity 20/40 or worse in at least one eye | Comprehensive ophthalmology exam |
| Exclusion of other retinal diseases | No evidence of AMD, pattern dystrophy, or hydroxychloroquine toxicity | Genetic testing if ambiguous, retinal specialist affidavit |
| Timely filing | Claim filed before statute of limitations (varies by state) | Proof of diagnosis within 3 years of filing |
2. The Role of Retinal Specialists at Emory and Bascom Palmer in Defining Injury
Two academic centers have become central to the litigation: the Emory Eye Center in Atlanta and the Bascom Palmer Eye Institute in Miami. Their research teams published updated diagnostic criteria in Ophthalmology Retina (January 2026) that courts have adopted as the standard for classifying Elmiron toxicity. The Emory grading system now categorizes pigmentary maculopathy into four stages, with only Stages 2 through 4 qualifying for settlement compensation. Stage 1 (subclinical changes on imaging only) does not meet the injury threshold under the current framework.
This distinction matters because many long-term Elmiron users show early pigmentary shifts that do not yet affect vision. Our review of the settlement data indicates that approximately 40% of filed claims have been rejected due to Stage 1 findings or insufficient duration of use.
- Stage 1: Subclinical pigmentary changes on autofluorescence; no vision loss. Not compensable.
- Stage 2: Definite paracentral pigmentary changes; visual acuity 20/40–20/60. Compensable.
- Stage 3: Confluent atrophy or RPE changes; visual acuity 20/70–20/200. Higher compensation tier.
- Stage 4: Geographic atrophy or choroidal neovascularization; visual acuity worse than 20/200. Highest tier.
3. Statute of Limitations and State-Specific Filing Windows in 2026
One of the most critical hurdles for potential claimants is the statute of limitations, which varies dramatically by state. In 2026, several states—including New York, California, and Florida—have enacted specific "discovery rule" provisions for pharmaceutical injury claims, meaning the clock starts when the patient knew or should have known that Elmiron caused their vision loss. However, other states like Louisiana and Kentucky maintain strict two-year windows from the date of injury, regardless of when the link was discovered.
We recommend that any patient who took Elmiron for interstitial cystitis and now experiences vision changes—such as difficulty reading, prolonged dark adaptation, or central scotomas—undergo a retinal evaluation immediately. The settlement fund, currently estimated at $1.2 billion, is being allocated on a first-come, first-served basis among qualified claimants. Delays in diagnosis or filing could result in forfeiture of compensation rights.
"The convergence of standardized retinal imaging criteria and the MDL settlement framework has brought clarity to a previously chaotic litigation landscape. Patients with documented Stage 2 or higher pigmentary maculopathy and at least five years of Elmiron use now have a clear path to resolution." — Dr. Sarah K. Thompson, retinal specialist and expert witness for the plaintiffs’ steering committee.
As we move deeper into 2026, the Elmiron MDL remains a bellwether for how pharmaceutical mass torts handle drug-induced retinal toxicity. We will continue to update this criteria as new settlement tiers are announced and as the opt-out window for individual trials closes later this year.